Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eiken Chemical Co., Ltd. (4549:JPX), powered by AI.
Eiken Chemical Co., Ltd. is currently trading at ¥2,658. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Eiken Chemical Co., Ltd. on Alpha Lenz.
Eiken Chemical Co., Ltd.'s P/E ratio is 41.0.
“Eiken Chemical Co., Ltd. trades at a P/E of 41.0 (premium valuation) with modest ROE of 5.0%.”
Ask for details →Eiken Chemical Co., Ltd. is a leading Japanese company specializing in the development, production, and marketing of in-vitro diagnostic reagents. Established in 1939, the company plays a crucial role in the healthcare industry by providing essential tools for accurate disease diagnosis and monitoring. Eiken Chemical is renowned for its innovative RUNNER® nucleic acid amplification technology, which has had substantial impacts in the fields of molecular diagnostics and infectious disease detection. Additionally, the company offers a wide range of diagnostic solutions, including reagents for detecting chronic and acute diseases and urinary and blood diagnostic tests. Eiken's products are vital for hospitals, laboratories, and clinics, facilitating timely and accurate patient care. The firm's commitment to research and development ensures the continuous enhancement of its diagnostic tools, reinforcing its market significance. In the financial market, Eiken Chemical Co., Ltd. is valued for its strong foothold in the diagnostic sector and its contribution to advancing medical testing technology in Japan and globally.
“Eiken Chemical Co., Ltd. trades at a P/E of 41.0 (premium valuation) with modest ROE of 5.0%.”
Ask for details →Eiken Chemical Co., Ltd. (ticker: 4549) is a company listed on JPX in the Healthcare sector (Medical Devices). It has approximately 702 employees. Market cap is $91.4B.
The current price is 2,658 with a P/E ratio of 41.01x and P/B of 2.1x.
ROE is 4.98% and operating margin is 7.40%. Annual revenue is $40.5B.